ABSTRACT
Diabetic wounds are susceptible to microbial infection. The treatment of these wounds requires a higher payload of growth factors. With this in mind, the strategy for this study was to utilize a novel payload comprising of Eudragit RL/RS 100 nanofibers carrying the bacterial inhibitor gentamicin sulfate (GS) in concert with recombinant human epidermal growth factor (rhEGF); an accelerator of wound healing. GS containing Eudragit was electrospun to yield nanofiber scaffolds, which were further modified by covalent immobilization of rhEGF to their surface. This novel fabricated nanoscaffold was characterized using scanning electron microscopy, Fourier transform infrared spectroscopy, and X-ray diffraction. The thermal behavior of the nanoscaffold was determined using thermogravimetric analysis and differential scanning calorimetry. In the in vitro antibacterial assays, the nanoscaffolds exhibited comparable antibacterial activity to pure gentemicin powder. In vivo work using female C57/BL6 mice, the nanoscaffolds induced faster wound healing activity in dorsal wounds compared to the control. The paradigm in this study presents a robust in vivo model to enhance the applicability of drug delivery systems in wound healing applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 641-651, 2018.
Subject(s)
Diabetes Mellitus, Experimental/pathology , Epidermal Growth Factor/pharmacology , Gentamicins/pharmacology , Nanofibers/chemistry , Recombinant Proteins/pharmacology , Tissue Scaffolds/chemistry , Wound Healing/drug effects , Animals , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Delayed-Action Preparations/pharmacology , Humans , Mice, Inbred C57BL , Microbial Sensitivity Tests , Nanocomposites/chemistry , Nanocomposites/ultrastructure , Nanofibers/ultrastructure , Polymers/chemistry , Temperature , Tissue Engineering , WettabilityABSTRACT
OBJECTIVE: To evaluate the antihyperglycemic activity of leaves of Hyptis suaveolens using streptozotocin model. METHODS: Hyptis suaveolens extract (HSE) 250 and 500 mg/kg body weight was administered orally to streptozotocin induced diabetes, once daily for 21 days. RESULTS: A significant reduction in blood glucose was observed in diabetic animals treated with HSE at different doses when compared with diabetic rats. Levels of triglyceride, total cholesterol, low density lipoprotein, very low density lipoprotein were decreased while administering HSE at different doses, compared with their control values in diabetic animals. CONCLUSIONS: Our results show that HSE possesses significant antihyperglycemic activity which might be attributed to stimulating effects on glucose utilization and antioxidant enzyme.
